bis-(5-morpholinopentyl) fumarate | 1448896-89-6

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: bis-(5-morpholinopentyl) fumarate
• 英文别名: bis(5-morpholin-4-ylpentyl) (E)-but-2-enedioate
• CAS: 1448896-89-6
• 化学式: C₂₂H₃₈N₂O₆
• 分子量: 426.554
• InChiKey: DFOXBFCQDPAVKC-BQYQJAHWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  30
• 可旋转键数：
  16
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.82
• 拓扑面积：
  77.5
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE
  申请人：XENOPORT, INC.

  公开号：US20130203753A1

  公开（公告）日：2013-08-08

  Morpholinoalkyl fumarates, pharmaceutical compositions comprising the morpholinoalkyl fumarates, and methods of using morpholinoalkyl fumarates and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed.

  Morpholino烯丙酸烷基酯，包含该类化合物的药物组合物，以及使用Morpholino烯丙酸烷基酯和药物组合物治疗神经退行性、炎症性和自身免疫性疾病的方法被披露，这些疾病包括多发性硬化症、牛皮癣、肠易激综合征、溃疡性结肠炎、关节炎、慢性阻塞性肺疾病、哮喘、帕金森病、亨廷顿病和肌萎缩侧索硬化症。
• Morpholinoalkyl Fumarate Compounds, Pharmaceutical Compositions, and Methods of Use
  申请人：XenoPort, Inc.

  公开号：US20140051705A1

  公开（公告）日：2014-02-20

  Morpholinoalkyl fumarates, pharmaceutical compositions comprising the morpholinoalkyl fumarates, and methods of using morpholinoalkyl fumarates and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed.
• US8952006B2
  申请人：——

  公开号：US8952006B2

  公开（公告）日：2015-02-10
• [EN] MORPHOLINOALKYL FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE<br/>[FR] COMPOSÉS DE FUMARATE DE MORPHOLINOALKYLE, COMPOSITIONS PHARMACEUTIQUES ET PROCÉDÉS D'UTILISATION
  申请人：XENOPORT INC

  公开号：WO2013119791A1

  公开（公告）日：2013-08-15

  Morpholinoalkyl fumarates, pharmaceutical compositions comprising the morpholinoalkyl fumarates, and methods of using morpholinoalkyl fumarates and pharmaceutical compositions for treating neurodegenerative, inflammatory, and autoimmune disorders including multiple sclerosis, psoriasis, irritable bowel disorder, ulcerative colitis, arthritis, chronic obstructive pulmonary disease, asthma, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are disclosed.
• [EN] METHODS OF USE FOR MONOMETHYL FUMARATE AND PRODRUGS THEREOF<br/>[FR] PROCÉDÉS D'UTILISATION DE FUMARATE DE MONOMÉTHYLE ET PROMÉDICAMENTS CORRESPONDANTS
  申请人：XENOPORT INC

  公开号：WO2014031901A1

  公开（公告）日：2014-02-27

  Methods of treating a disease in a patient comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound selected from: (i) monomethyl fumarate, (ii) a prodrug of monomethyl fumarate, and (iii) combinations thereof, wherein the disease is chosen from balo concentric sclerosis, bronchiolitis obliterans organizing pneumonia, central nervous system vasculitis, Charcott- Marie-Tooth Disease, childhood ataxia with central nervous system hypomyelination, diabetic retinopathy, graft versus host disease, monomelic amyotrophy, neurodegeneration with brain iron accumulation, neurosarcoidosis, pareneoplastic syndromes, subacute necrotizing myelopathy, Susac syndrome and transverse myelitis.